| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |